Literature DB >> 2311310

Renal function during calcitriol therapy in chronic renal failure.

M Bertoli1, G Luisetto, A Ruffatti, M Urso, G Romagnoli.   

Abstract

Some authors have reported that vitamin D treatment worsens renal function. We studied 10 patients with stable renal function, who were given calcitriol (0.5 micrograms/day) for a 4-month period. Creatinine and inulin clearance were performed at the beginning and at the end of the treatment. Although serum creatinine increased and creatinine clearance decreased, inulin clearance did not show significant variations. Furthermore, serum creatinine fell to the baseline value within 60 days after discontinuation of vitamin D therapy. The increased serum creatinine may be explained by an augmented release from muscular tissue, probably due to the improvement of uremic myopathy induced by calcitriol.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2311310

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  10 in total

Review 1.  Bone and mineral disorders in pre-dialysis CKD.

Authors:  Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

Review 2.  Active vitamin D treatment for reduction of residual proteinuria: a systematic review.

Authors:  Martin H de Borst; Reza Hajhosseiny; Hector Tamez; Julia Wenger; Ravi Thadhani; David J A Goldsmith
Journal:  J Am Soc Nephrol       Date:  2013-08-08       Impact factor: 10.121

3.  Paricalcitol for secondary hyperparathyroidism in renal transplantation.

Authors:  Matias Trillini; Monica Cortinovis; Piero Ruggenenti; Jorge Reyes Loaeza; Karen Courville; Claudia Ferrer-Siles; Silvia Prandini; Flavio Gaspari; Antonio Cannata; Alessandro Villa; Annalisa Perna; Eliana Gotti; Maria Rosa Caruso; Davide Martinetti; Giuseppe Remuzzi; Norberto Perico
Journal:  J Am Soc Nephrol       Date:  2014-09-05       Impact factor: 10.121

4.  Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial.

Authors:  Eleonora Riccio; Massimo Sabbatini; Dario Bruzzese; Ivana Capuano; Silvia Migliaccio; Michele Andreucci; Antonio Pisani
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

5.  Treatment with oral paricalcitol in daily clinical practice for patients with chronic kidney disease stage 3-4: a preliminary study.

Authors:  Dimitrios Hadjiyannakos; Vassilis Filiopoulos; Sofia Trompouki; Makroui Sonikian; Ioannis Karatzas; Konstantinos Panagiotopoulos; Dimosthenis Vlassopoulos
Journal:  Clin Kidney J       Date:  2013-02-05

6.  Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial.

Authors:  Thomas Larsen; Frank H Mose; Jesper N Bech; Erling B Pedersen
Journal:  BMC Nephrol       Date:  2013-07-26       Impact factor: 2.388

Review 7.  Vitamin D Sources, Metabolism, and Deficiency: Available Compounds and Guidelines for Its Treatment.

Authors:  Ligia J Dominguez; Mario Farruggia; Nicola Veronese; Mario Barbagallo
Journal:  Metabolites       Date:  2021-04-20

8.  A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer.

Authors:  T Gulliford; J English; K W Colston; P Menday; S Moller; R C Coombes
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640

Review 9.  Effect of Vitamin D Receptor Activators on Glomerular Filtration Rate: A Meta-Analysis and Systematic Review.

Authors:  Qian Zhang; Ming Li; Tiansong Zhang; Jing Chen
Journal:  PLoS One       Date:  2016-01-26       Impact factor: 3.240

10.  Patterns of progression of chronic kidney disease at later stages.

Authors:  Fernando Caravaca-Fontán; Lilia Azevedo; Enrique Luna; Francisco Caravaca
Journal:  Clin Kidney J       Date:  2017-07-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.